Fig. 5: Assessment of eDRS4C (PREDICT T1D) miRNAs in predicting drug responsiveness at the study baseline in the imatinib T1D trial.

a, PREDICT T1D miRNAs were profiled in the imatinib study participants from the drug intervention arm at the study baseline. Individuals were stratified to the UQ and LQ of response to therapy (C-peptide levels assessed at 1 year). b, The UMAP dimensionality reduction algorithm was applied to the expression profile of all 50 miRNAs across UQ and LQ study participants, leading to two broad clusters representing drug response at 1 year. c, Decision tree for key variables from our eDRS4C that aid in the segregation of UQ and LQ responders to imatinib therapy. d, The expression of the top four miRNAs in the decision tree was assessed between UQ and LQ participants using a one-sided Welch’s t-test. e, Key pathways along with their Gene Ontology (GO) IDs (y axis), which are targeted by the top four miRNAs (x axis) in the decision tree, are shown using a bubble plot. The size of the bubble indicates the number of target genes (written next to each bubble), while the color of the bubble denotes the significance of the miRNA target pathway interaction as obtained using the miRPathDB tool. A color scale for the adjusted P value is also provided. A hypergeometric test with Benjamini–Hochberg adjustment was used for the enrichment analyses on miRPathDB. f, Venn diagram presenting 36 genes in the tyrosine kinase pathway that are targeted by hsa-miR-27b-3p (GO:0004712) and nine genes involved in the tyrosine kinase pathway inhibited by imatinib.